Global Partners L.P. (GLP)
NYSE NYSE Primary 
3 GLP-1 Stocks to Buy Now For Big Long-Term Gains
The surge in interest investors have displayed for companies delivering weight loss drugs has been impressive.
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment.
First Results from Lexaria's Second GLP-1 Human Pilot Study
Trend toward higher overall absorption under fed conditions evidenced with DehydraTECH®-processed Rybelsus® KELOWNA, BC / ACCESSWIRE / August 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that the first results from human pilot study #2, GLP-1-H24-2 (the "Study"), have been received. Lexaria's DehydraTECH®-processed Rybelsus® evidenced a trend toward higher overall absorption compared to Rybelsus® that was not processed with DehydraTECH.
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
While Eli Lilly & Co. and Novo Nordisk dominate the obesity-drug market, there's a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, Jefferies analysts said in a research note Monday.
These Were the Top-Selling GLP-1 Drugs Last Quarter From Eli Lilly and Novo Nordisk
Eli Lilly and Novo Nordisk's top diabetes drugs each brought in more than $3 billion in sales last quarter. Ozempic has been on the market for longer, but its growth rate isn't as impressive as that of other drugs.
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide Select DehydraTECH-CBD formulations appear to continue to outperform DehydraTECH-semaglutide KELOWNA, BC / ACCESSWIRE / August 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received and can now report on 8-week body weight results from ongoing animal study WEIGHT-A24-1 (the "Study"). This Study is the only study carried out anywhere in the world today, to evaluate the relative performance of liraglutide processed with DehydraTECH.
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutide Select DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks KELOWNA, BC / ACCESSWIRE / August 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) were the top performers in the Study at day 56, with blood sugar level reductions of 2.50%, 1.90% and 1.53% respectively.
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company reported its Q2 FY24 earnings where revenue and Adjusted EBITDA grew 52% and 270% YoY respectively, as subscribers opting for Personalized Solutions grew over 164% YoY. While Hims generated close to $15M in Q2 from GLP-1 medications, it is simultaneously innovating and expanding its personalized solutions across its tenured and new specialties.
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
Eli Lilly's sales grew by 36% last quarter, largely due to the success of two products. The company has a promising molecule, tirzepatide, which has shown that it can help people lose significant weight.
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Hims just reported record Revenue, Profits, and Cash Flows, signifying improving fundamentals. This was driven by robust growth in its core offerings as well as the launch of its new Weight Loss offering. Demand for Hims products is so strong that management raised Revenue guidance by more than $100M.
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Hims & Hers is offering customers access to compounded GLP-1 weight loss drugs. Compounded drugs are only available when there's a shortage.
